Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours Β· Estimated delivery Aug 23 - Aug 28
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
It binds to the GHRH receptors in the anterior pituitary gland to stimulate the pulsatile secretion of growth hormone
They observed that Monospora and Enterobacteriaceae were predominant in freshwater, while halophilic Vibrio was the predominant genus in seawater
Curr Opin Struct Biol
Self-administration is not routinely offered in the NHS unless there are exceptional circumstances and a formal arrangement is in place
Tumor size and weight were significantly decreased, corresponding with a reduction in MDSC numbers and a loss of their immunosuppressive characteristics, while important anti-tumoral genes were upregulated [88]
US$ 29.83
US$ 29.34
US$ 28.69
